These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19812537)

  • 41. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
    Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adherence to mineral and bone disorder clinical practice guidelines in chronic kidney disease.
    Panawong W; Chaiyakum A; Pongskul C
    J Med Assoc Thai; 2011 Oct; 94(10):1175-83. PubMed ID: 22145501
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4-5.
    Gravesen E; Hofman-Bang J; Lewin E; Olgaard K
    Scand J Clin Lab Invest; 2013 Mar; 73(2):107-16. PubMed ID: 23281842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease.
    Muras K; Masajtis-Zagajewska A; Nowicki M
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1901-8. PubMed ID: 24092829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of vitamin D deficiency and consequences for PTH reference values.
    Deckers MM; de Jongh RT; Lips PT; Penninx BW; Milaneschi Y; Smit JH; van Schoor NM; Blankenstein MA; Heijboer AC
    Clin Chim Acta; 2013 Nov; 426():41-5. PubMed ID: 24012652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of four different PTH methods on the classification of chronic kidney disease patients according to the new KDIGO guideline.
    Ten BE; Van Veen MC; Vervloet MG; Fischer JC; Koopman MG; Van Dam B
    Clin Lab; 2012; 58(7-8):719-24. PubMed ID: 22997972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Parathyroid hormone metabolism and signaling in health and chronic kidney disease.
    Evenepoel P; Bover J; Ureña Torres P
    Kidney Int; 2016 Dec; 90(6):1184-1190. PubMed ID: 27653840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum sirtuin 1 is independently associated with intact PTH among patients with chronic kidney disease.
    Bielach-Bazyluk A; Zbroch E; Czajkowska K; Koc-Zorawska E; Kakareko K; Rydzewska-Rosolowska A; Hryszko T
    Clin Interv Aging; 2021; 16():525-536. PubMed ID: 33790547
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Parathyroid Hormone Measurement in Chronic Kidney Disease: From Basics to Clinical Implications.
    Kritmetapak K; Pongchaiyakul C
    Int J Nephrol; 2019; 2019():5496710. PubMed ID: 31637056
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Establishment of reference values in a healthy population and interpretation of serum PTH concentrations in hemodialyzed patients according to the KDIGO Guidelines using the Lumipulse® G whole PTH (3rd generation) assay.
    Cavalier E; Salsé M; Dupuy AM; Bargnoux AS; Watar F; Souberbielle JC; Delanaye P; Cristol JP
    Clin Biochem; 2018 Apr; 54():119-122. PubMed ID: 29501417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A different interaction between parathyroid hormone, calcitriol and serum aluminum in chronic kidney disease; a pilot study.
    Azik FM; Ekim M; Sakallioglu O; Aydin A
    Int Urol Nephrol; 2011 Jun; 43(2):467-70. PubMed ID: 20535635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Features of chronic renal disease in children.
    Ivanova ON; Savvina NA; Egorova VE
    Wiad Lek; 2016; 69(3 pt 2):530-531. PubMed ID: 27717939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adenine-induced chronic kidney disease induces a similar skeletal phenotype in male and female C57BL/6 mice with more severe deficits in cortical bone properties of male mice.
    Metzger CE; Swallow EA; Stacy AJ; Allen MR
    PLoS One; 2021; 16(4):e0250438. PubMed ID: 33891630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Malnutrition-Inflammation Complex Syndrome: A Cause of Low Parathyroid Hormone in Patients With Chronic Kidney Disease.
    Raj R; Kadiyala A; Patel C
    Cureus; 2021 Dec; 13(12):e20324. PubMed ID: 35028221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rebuttal: PTH--a particularly tricky hormone: why measure it at all in kidney patients?
    Sprague SM; Moe SM
    Clin J Am Soc Nephrol; 2013 Feb; 8(2):321. PubMed ID: 23160258
    [No Abstract]   [Full Text] [Related]  

  • 57. Alkaline phosphatase: better than PTH as a marker of cardiovascular and bone disease?
    Lau WL; Kalantar-Zadeh K; Kovesdy CP; Mehrotra R
    Hemodial Int; 2014 Oct; 18(4):720-4. PubMed ID: 25597344
    [No Abstract]   [Full Text] [Related]  

  • 58. The path to the standardization of PTH: Is this a realistic possibility? a position paper of the IFCC C-BM.
    Cavalier E; Vasikaran S; Bhattoa HP; Heijboer AC; Makris K; Ulmer CZ
    Clin Chim Acta; 2021 Apr; 515():44-51. PubMed ID: 33412144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Determination of parathyroid hormone: from radioimmunoassay to LCMS/MS.
    Cavalier E
    Clin Chem Lab Med; 2023 Apr; 61(5):946-953. PubMed ID: 36640443
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Study of Red Cell Fragility in Different Stages of Chronic Kidney Disease in Relation to Parathyroid Hormone.
    Panda S; Mishra A; Jena M; Rout SB; Mohapatra S
    J Clin Diagn Res; 2017 Aug; 11(8):BC29-BC32. PubMed ID: 28969115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.